Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-18
2005-10-18
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S385000
Reexamination Certificate
active
06956025
ABSTRACT:
The invention relates to covalently cross-linked mammalian hemoglobins, to which polyalkylene oxides are covalently linked. Such hemoglobins are surprisingly compatible with proteins of human and animal plasma, under all the possible conditions within the vascular system of the body. The invention furthermore relates to the production of these cross-linked hemoglobins linked with polyalkylene oxides, as well as to their use as artificial intravasal oxygen carriers in the human or animal organism or in individual organs.
REFERENCES:
patent: 4001200 (1977-01-01), Bonsen et al.
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4857636 (1989-08-01), Hsia
patent: 5234903 (1993-08-01), Nho et al.
patent: 5312808 (1994-05-01), Shorr et al.
patent: 5386014 (1995-01-01), Nho et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5478805 (1995-12-01), Shorr et al.
patent: 24 99 885 (0000-01-01), None
patent: 0 26 07 706 (1976-01-01), None
patent: 24 49 885 (1976-08-01), None
patent: 2616 086 (1977-03-01), None
patent: 30 26 398 (1981-03-01), None
patent: 30 26 398 (1981-03-01), None
patent: 0 31 30 770 (1983-01-01), None
patent: 95 107 280 (0000-01-01), None
patent: 95 107 289 (0000-01-01), None
patent: 97 100 790 (0000-01-01), None
patent: 0 067 029 (1982-12-01), None
patent: 0 067 029 (1982-12-01), None
patent: 0 069 026 (1983-01-01), None
patent: 0 201 618 (1986-11-01), None
patent: 0 206 448 (1986-12-01), None
patent: 0 528 841 (1993-03-01), None
patent: 0 854 151 (1998-07-01), None
patent: 0 854 151 (1998-07-01), None
patent: WO 91/07190 (1991-05-01), None
Ton T. Hai et al: “Polymerization of Diaspirin Crosslinked Hemoglobin (DCLHb) with PEG Activated with Benzenesulfonate Bearing Electron-Withdrawing Groups”; Tetrahedron 55 (1999) 2147-2156 XP-002183148.
T.T. Hai et al: “Diaspirin Crosslinked Hemoglobin (DCLHb) Polymerization”; Art. Cells, Blood Subs., And Immob. Biotech., 22(3) 923-931 (1984) XP-001039974.
Fitzgerald, L.R; “Cutaneous Respiration in Man”; Cutaneous Respiration, Division of Anatomy, University of Tennessee Medical Units, Memphis, TN, Jul. 1957, pp. 325-336, vol. 37.
Barnikol, W.K.R.et al; “Die Feinstruker der Sauerstoff-Hämoblogin-Bindung als Hilfsmittel zum Studium pharmakologischer Wirkungen . . . ”; Physiologisches Institut der Johannes Guttenberg-Germany, Funkt. Biol. med. 2, (1983), pp. 245-249.
Kothe, N., et al; “Characterization of a modified, stroma-free hemoglovin solution as an oxygen-carrying plasma substitute”; Scientific Department of Biotest Pharma GmbH, Frankfurt, Germany; Surgery, Gynecology & Obstertrics, Dec. 1985, vol. 161, pp. 563-569.
Bosman, R.J. et al. “Free Polymerized Hemoglobin Versus Hydroxyethyl Starch in Resuscitation of Hypovolemic Dogs”, Anesth. Analg. 75, pp. 811-817.
Pabst, R.; “Sauerstofftransport mit stromafreien Hämoglobinlösungen und Fluorocarbonen”; Med. Klin. 72 (1977) pp. 1555-1562, vol. 39.
Chang, T.M.S., “How safe are modified hemoglobins?”Blood Substitutes: Present and Future Perspectives, Elsevier Science, Amsterdam (1998).
Keipert, et al, “Pyridoxylated Polyhemoglobin as a red cell substitute for resuscitation of lethal hemorrhagic shock in conscious rats”; Biomat. Med. Dev. Art. Org. 13 (1&2), pp. 1-15 (1935).
Hirlinger, W.K., et al, “Effects of a Partial Exchange with Fluosol DA 20% on healthy Pig”, Anästhesist 31, pp. 660-666 (1982).
Keipert, et al; “Pyridoxylated-polyhemoglobin solution: a low viscosity oxygen-delivering blood replacement fluid with normal oncotic pressure and long-term storage feasibility”; Artificial Cells & Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Canada, pp. 185-197.
Hunt, C.A., et al, “Synthesis and Evaluation of a Protypal Artificial Red Cell”, Science, 230: pp. 1165-1168 (1985).
Farmer, M.C.; et al; “Preclinical data and clinical trials with diaspirin cross-linked hemoglobin”; Artificial Red Cells, edited by E. Tsuchida, (1995) John Wiley & Sons pp. 177-185.
Keipert P.E., et al, “Metabolism, Distribution, and Excretion of HbXL: A Nondissociation Interdimerically Crosslinked Hemoglobin with Exceptional Oxygen Offloading Capability”, Chang, T.M.S., Geyer R. P. (Eds.): Blood Substitutes, Marcel Dekker, New York (1989).
Chang T.M.S., “Modified Hemoglobin as Red Cell Blood Substitutes”, Biomat. Art. Cells, Art. Org. 15(2), pp. 323-328 (1987).
Friedman H.J., et al, “In Vivo Evaluation of Pyridoxylated-Polymerized Hemoglobin Solution”, Surg. Gynecol., Obstet.; 159, pp. 429-435 (1984).
Bakker, J.C. et al; “Properties of hemoglobin interdimerically cross-linked with NFPLP”; Biomet. Art. Cells & Immob, Bio., vol. 16, pp. 635-636 (1988).
Barnikol, W.K.R. et al, “Hyperpolymeric Hemoglobins and Artifical Oxygen Carriers. An Innovative Attempt at Medical Development”, Therapiewoche 46: pp. 811-815 (1996).
Pötschke, H. et al; “Vernetzte globuläre proteine -eine neue klasse halbsynthetischer makromoleküle: . . . ”; Macromol. Chem. Phys. 197, pp. 1419-1437 (1996).
Barnikol, W.K.R., “the Influence of Glutardialdehyde on the Oxygen Cooperativity of Human Hemoglobin”, Pflügers Archi 406: R 61 (1986).
Conover et al, “The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models”; Art. Cells, Blood Subst. Immobil. Biotech. 27: pp. 93-107 (1999).
Looker, D, et al; “A human recombinant haemoglobin designed for use as a blood substitute”; Nature. vol. 356, Mar. 19, 1992; pp. 258-260.
Xue, H. et al; “Preparation of conjugated hemoglobins”; Methods in Enzymology, vol. 231, pp. 308-323 (1994).
Barnikol, W.K.R., et al; “Highly polymerized human haemoglobin as an oxygen-carrying blood subsititute”, Advances in Experimental Medicine and Biology, vol. 215, pp. 129-134 (1987).
Tam, et al., “Blood replacement in dogs by dextran-hemoglobin”; Can. J. Biochem, vol. 56 (1978); pp. 981-984.
Gould, et al; “The clinical development of human polymerized hemoglobin”; Blood Substitutes: principles, methods, products and clinical trials, edited by Thomas Ming Swi Chang (1998).
Bakker et al.; “Preparation and characterization of crosslinked and polymerized hemoglobin solutions”, Biomat., Art. Cells & Immob. Biotec., 20(2-4), pp. 233-241 (1992).
“Points to consider in the safety evaluation of hemoglobin-based oxygen carriers”; Center for Biologies Evaluation and Research; Transfusion vol. 31, 4 (1991) pp. 369-371.
Pötzschke, H. et al “A novel method for determining molecular weights of widely distributed polymers with the help of gel photography and viscosimetry using hemoglobin hyperpolymers as examples”, Macromolecular chemistry and Physics 197, pp. 3229-3250 (1996).
Barnikol, W.K.R. et al, “An improved modification of the micro-method according to the measurement of Niesel and Thews for O2-Hb-binding curves in whole blood and concentrated Hb solutions”, Respiration 36, pp. 86-95 (1978).
Sharma et al; “Role of no mechanism in cardiovascular effects of diaspirin cross-linked hemoglobin in anesthetized rats”; American Physiological Society; pp. 1379-1388 (1995).
Rohlfs et al; “Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide”; The Journal of Biological Chemistry, vol. 273, No. 20, Issue of May 15, pp. 12128-12134 (1998).
Rodeberg et al; “Nitric oxide: and overview”; The AmericanJournal of Surgery, vol. 170, Sep. 1995, pp. 292-303.
Vogel, et al; “Coronary constrictor effect of stroma-free hemoglobin solutions”; The American Journal of Physiol., vol. 251; pp, H413-H420 (1986
Mondesi Robert B.
Norris McLaughlin & Marcus P.A.
Sanguibiotech GmbH
Wax Robert A.
LandOfFree
Mammalian haemoglobin compatible with blood plasma,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammalian haemoglobin compatible with blood plasma,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian haemoglobin compatible with blood plasma,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3482417